Why the study?
What are the genetic modifiers of heart failure risk and outcome?
What are the genetic modifiers of heart failure risk and outcome?
Advances in genotyping are identifying specific risk alleles for heart failure, highlighting the potential for future genotype-directed heart failure management.
Genetic variants may modify HF risk and outcomes; leaves open genotype-directed management pending prospective trials.
PURPOSE OF REVIEW: Genetic factors contribute to overall heart failure risk, but specific risk alleles are only beginning to be identified. Here, new results from candidate gene and genome-wide polymorphism studies that have delineated associations between polymorphic genes and heart failure are reviewed in the context of their likely clinical translation and implementation. RECENT FINDINGS: Recent data support and extend consequences of genetically variant β1-adrenergic receptors and G-protein receptor kinase 5 on heart failure. New genome-wide and subgenome-wide studies have identified unexpected genetic modifiers of heart failure risk and outcome, suggesting that determinants of heart failure onset and progression are distinct, and pointing to unexpected genetic interactions in cardiac disease. SUMMARY: Advances in high-throughput genotyping and resequencing herald a rapid expansion of genomic information in heart failure. With identification of putative heart failure risk alleles, the next step will be prospective clinical trials evaluating the benefits of genotype-directed heart failure management.
No takes yet. Share an insight, caveat, or question.
Gerald W. Dorn (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: